Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subretinal injection in the USH1CR31* pig model leads to chorioretinal atrophy that limits evaluation of efficacy of an AAV-mediated gene therapy.

Experimental eye research·2026
Same author

Microperimetry as an Outcome Measure Improves Patient Eligibility and Efficacy Detection in RPGR Gene Therapy Trials.

American journal of ophthalmology·2026
Same author

Gene therapy development for retinal diseases.

Handbook of clinical neurology·2026
Same author

Centripetal Retinal Degeneration Follows an Exponential Decay and May Be Reversed Following Gene Therapy.

American journal of ophthalmology·2026
Same author

Exploring fundus-controlled mesopic and scotopic perimetry in inherited retinal disease.

Acta ophthalmologica·2026
Same author

Precision Is Not Enough: When Tools Outpace Translation in Ocular Gene Therapy.

Genes·2026
Same journal

RETRACTED: Kim et al. The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Regulating the Visceral Adipose-Tissue Function. <i>Int. J. Mol. Sci.</i> 2017, <i>18</i>, 846.

International journal of molecular sciences·2026
Same journal

Correction: Mahmud et al. Thymoquinone Attenuates NF-κβ Signalling Activation in Retinal Pigment Epithelium Cells Under AMD-Mimicking Conditions. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 11473.

International journal of molecular sciences·2026
Same journal

Correction: Borovikov et al. The Twisting and Untwisting of Actin and Tropomyosin Filaments Are Involved in the Molecular Mechanisms of Muscle Contraction, and Their Disruption Can Result in Muscle Disorders. <i>Int. J. Mol. Sci</i>. 2025, <i>26</i>, 6705.

International journal of molecular sciences·2026
Same journal

Correction: Molagoda et al. Flavonoid Glycosides from <i>Ziziphus jujuba</i> var. <i>inermis</i> (Bunge) Rehder Seeds Inhibit α-Melanocyte-Stimulating Hormone-Mediated Melanogenesis. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 7701.

International journal of molecular sciences·2026
Same journal

Correction: Guo et al. Integrated Transcriptomic and Metabolomic Analysis Reveals the Molecular Regulatory Mechanism of Flavonoid Biosynthesis in Maize Roots Under Lead Stress. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 6050.

International journal of molecular sciences·2026
Same journal

Correction: Chang et al. Improvement of Carbon Tetrachloride-Induced Acute Hepatic Failure by Transplantation of Induced Pluripotent Stem Cells Without Reprogramming Factor c-Myc. <i>Int. J. Mol. Sci.</i> 2012, <i>13</i>, 3598-3617.

International journal of molecular sciences·2026
See all related articles

Related Experiment Video

Updated: Jul 15, 2025

Enrichment of Bruch's Membrane from Human Donor Eyes
10:22

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

12.1K

Choroideremia: The Endpoint Endgame.

Maram E A Abdalla Elsayed1,2, Laura J Taylor1,2, Amandeep S Josan1,2

  • 1Oxford Eye Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford OX3 9DU, UK.

International Journal of Molecular Sciences
|September 28, 2023
PubMed
Summary
This summary is machine-generated.

Choroideremia, an X-linked retinal disease, causes progressive vision loss. Gene therapy shows promise for treatment, and this review analyzes clinical trial data to guide future strategies for this inherited retinal degeneration.

Keywords:
AAVCHM geneREP1antisense oligonucleotideschoroideremiaclinical trialsendpointsgene therapynonsense suppression therapyoutcome measures

More Related Videos

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K
Assessment and Characterization of Hyaloid Vessels in Mice
08:22

Assessment and Characterization of Hyaloid Vessels in Mice

Published on: May 15, 2019

9.2K

Related Experiment Videos

Last Updated: Jul 15, 2025

Enrichment of Bruch's Membrane from Human Donor Eyes
10:22

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

12.1K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K
Assessment and Characterization of Hyaloid Vessels in Mice
08:22

Assessment and Characterization of Hyaloid Vessels in Mice

Published on: May 15, 2019

9.2K

Area of Science:

  • Ophthalmology
  • Genetics
  • Retinal Degeneration

Background:

  • Choroideremia is an X-linked inherited retinal degeneration.
  • It causes progressive loss of photoreceptors and choriocapillaris due to retinal pigment epithelium degeneration.
  • Symptoms include night blindness and peripheral vision loss, progressing to central vision impairment.

Purpose of the Study:

  • To review lessons learned from choroideremia clinical trials.
  • To analyze current endpoints used in choroideremia research.
  • To propose a future strategy for effective clinical trials.

Main Methods:

  • Literature review of published clinical trials in choroideremia.
  • Analysis of outcome measures and endpoints in gene therapy studies.
  • Synthesis of findings to inform future trial design.

Main Results:

  • Clinical trials have provided valuable insights into managing choroideremia.
  • Standardized endpoints are crucial for evaluating treatment efficacy.
  • Gene therapy is a promising approach for halting disease progression.

Conclusions:

  • Further refinement of clinical trial designs is needed for choroideremia.
  • Optimized endpoints will accelerate the development of effective therapies.
  • Gene therapy holds significant potential for treating this condition.